‘Kamada’ Obtains FDA Approval For Cystic Fibrosis Drug Trial

Israeli bio-pharmaceutical company Kamada announced that it has obtained FDA approval to conduct a clinical trial in the US for the company’s next generation drug for the treatment of cystic fibrosis. The drug is an inhalable version of company’s AAT drug (Alpha-1 Antitrypsin deficiency). The current FDA approval is partly based on successful pre-clinical trials of the drug. Company president and CEO, David Tsur, said they expect to shortly complete the preparations for the trial in order to obtain approval for the drug in the US market. View and share